CHMP Backs Galcanezumab for Migraine Prevention CHMP Backs Galcanezumab for Migraine Prevention

The EMA committee has recommended marketing authorization for a second CGRP antagonist for migraine prevention, following its first-in-class approval recommendation for erenumab in May.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news